Introduction:: Fixed-Dose Combinations (FDCs) combine two or more active components into a single dosage form, addressing active ingredient incompatibilities and enabling diverse release profiles through innovative formulation strategies. They enhance patient compliance, target multiple disease pathways for synergistic effects, and are increasingly important for global health priorities. Methods:: This review synthesizes recent literature, regulatory updates, and clinical evidence on FDCs, focusing on advanced formulation approaches, manufacturing processes, market trends, and post-marketing evaluations. Regulatory frameworks from the USFDA, EMA, and CDSCO were compared to identify approval pathway differences and opportunities for harmonization. Results:: Innovative dosage forms, including co-crystallization, soft gelatin capsules with liquid actives, and cardiovascular polypills, have demonstrated improved therapeutic outcomes and costeffectiveness. In India, FDCs dominate antibiotic use both clinically and economically. Comparative regulatory analysis revealed significant procedural variations, potentially impacting global adoption. Clinical and post-market data confirm the safety, efficacy, and practicality of approved FDCs, supporting their role in addressing unmet medical needs. Discussion:: FDCs simplify complex regimens, improve adherence, and can facilitate the introduction of first- and best-in-class medicines. However, challenges include formulation instability, analytical difficulties in multi-component quantification, manufacturing complexity, and compliance monitoring. Balancing innovation with robust regulatory oversight and fostering international collaboration will be essential for maximizing their potential. This review provides a comprehensive understanding of the evolving FDC landscape, guiding stakeholders in strategic development and implementation for improved healthcare outcomes.
Jain et al. (Wed,) studied this question.